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and decreases in severity of OM earlier (from 1 to 3 days) using
the MTS than their physicians who were using the 3 OM
clinical scales. The self-reported OM pain score was worst at
day 5 for MTS, compared to day 7 for the 3 clinical scales.
Correlation of the MTS/MTS-AL scores at days 7 and 14 was
strongest with the WHO scale (0.25–0.55). MTS/MTS-AL
correlation was next strongest with the WCCNR scale (0.27–
0.49), followed by the RTOG scale (0.29–0.44). Similarly, the
changes in mean scores were signiﬁcantly correlated between
MTS (0.29) or 4 of 5 MTS-AL (0.28–0.33) and the WHO scale.
Conclusion: The patient self-reported severity and impact of
OM measure correlated well with the clinical measures, espe-
cially with the WHO scale. In addition, the patient self-reported
measure can consistently detect changes (both increases and
decreases) in the severity of OM earlier than can any of the OM
clinical measures.
Table 1. Correlation of MTS Questions With WHO Clinical OM
Scale
MTS Questions
Mean Score Correlation Coefficient (r)




MTS (mouth and throat
soreness) 0.46 (n  174) 0.49 (n  113) 0.29 (n  100)
MTS-S (swallowing) 0.50 (n  174) 0.38 (n  113) 0.29 (n  100)
MTS-D (drinking) 0.54 (n  173) 0.43 (n  113) 0.30 (n  99)
MTS-E (eating) 0.55 (n  173) 0.41 (n  113) 0.33 (n  99)
MTS-T (talking) 0.45 (n  172) 0.35 (n  113) 0.28 (n  99)
MTS-SL (sleeping) 0.30 (n  170) 0.25 (n  113) 0.08 (n  97)
NOTE: P-values are Day 7: p 0.001; Day 14: p 0.008; Change
in mean score: p 0.005 (for MTS, MTS-S, MTS-D, MTS-E,
MTS-T); Change in mean score: p  0.428 (for MTS-SL
only).
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LONG-TERM QUALITY OF LIFE IS NOT AFFECTED BY AGE IN AML/MDS
PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Shahjahan, M., Alamo, J., Giralt, S., Detry, M., Munsell, M.,
Estey, E., Champlin, R., de Lima, M. University of Texas M.D.
Anderson Cancer Center, Houston, TX.
Objective: Allogeneic hematopoietic stem cell transplantation
(alloHSCT) can have signiﬁcant impact on patients’ quality of
life (QOL) in the long term. We seek to describe QOL of
long-term survivors with AML/MDS and compare QOL as a
function of age at transplant. Methods: Between January 1976
and September 2001, 544 adult AML/MDS patients received
alloHSCT at our institution. Long-term survivorship was de-
ﬁned as survival in remission beyond 2 years post-HSCT be-
cause failure rate stabilized in the third year. A total of 129
(24%) patients in remission for at least 2 years were eligible.
QOL was assessed with Functional Assessment of Cancer Ther-
apy-Bone Marrow Transplant (FACT-BMT) questionnaire
measuring physical, functional, social/family, and emotional
well-being (PWB, FWB, SFWB, EWB), including doctor–pa-
tient relationship (RWD). An additional concern (AC) subscale
also asked questions related to bone marrow transplantation.
Response rate was 68%. A higher score on the FACT-BMT
reﬂected a higher QOL. Demographic and clinical data were
collected from medical records and clinical database. Results:
The median patient age at transplantation was 38.44 years
(range, 18.54–68.08 years). The study group comprised 47
males and 35 females, 70 with a diagnosis of AML and 12 with
a diagnosis of MDS. Conditioning was with reduced intensity
regimen (RI) in 29 cases and myeloablative regimen (MA) in 53
cases. The stem cell source was the bone marrow in 52 cases and
peripheral blood in 30 cases. Disease status at HSCT was
complete remission in 40 cases, relapsed in 37 cases, and un-
treated disease in 5 cases. Median follow-up time was 4.53 years
(range, 2.0–21.1 years). There were no signiﬁcant differences
between the older and younger patients (above and below the
median age at transplant) on the PWB, SFWB, EWB, FWB,
and RWD subscales. On the AC subscale, older patients had
higher QOL scores than younger patients (mean score, 37.97 vs
33.25, respectively; P  .005). There were no signiﬁcant differ-
ences in QOL scores between patients receiving RI and MA
regimen in all but the AC subscale where RI group had a higher
score (39.00 vs 33.34, respectively; P  .001). Acute graft-
versus-host disease (GVHD) did not impact long-term QOL,
but lack of chronic GVHD was associated with better QOL
score in the PWB, EWB, FWB, and AC subscales (PWB, 25.04
vs 20.62, P  .005; EWB, 21.77 vs 18.98, P  .003; FWB, 22.91
vs 18.00, P  .008; AC, 40.00 vs 34.28, P  .002). Conclusion:
Older age at transplantation did not affect the QOL in long-
term survivors with AML/MDS after alloHSCT.
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TOPOIETIC CELL TRANSPLANTATION (HCT)
Hingorani, S.R.1, Guthrie, K.2, Schoch, G.2, McDonald, G.D.1,2 1Uni-
versity of Washington, Seattle, WA; 2Fred Hutchinson Cancer Research
Center, Seattle, WA.
CKD has been reported in 20% of adult and 62% of children in
the years following HCT, usually becoming apparent 6–12 months
after transplant. Mortality rates are higher in patients with CKD in
this setting than in transplantation recipients who retain normal
renal function. Although there are numerous case series describing
CKD in the setting of HCT, they involve relatively small cohorts
of patients. We examined the frequency of CKD and risk factors
for its development in a large cohort of patients transplanted over
a 10-year time span.Methods:We reviewed data from consecutive
patients who received their ﬁrst transplantation between 1991 and
2002 and who had at least 2 serum creatinine values between days
100 and 540 posttransplantation, and at least 1 measurement
within 3 months of day 365 or death, whichever came ﬁrst. CKD
was deﬁned as a serum creatinine level 1.5 mg/dL in men, 1.3
mg/dL in women and  0.9 mg/dL in children at 2 or more times
during day 100–540 posttransplantation. Putative risk factors an-
alyzed included demographic characteristics, type of transplanta-
tion, conditioning regimen (including irradiation) and comorbidi-
ties such as acute graft-versus-host disease (GVHD) and acute
renal failure (ARF), deﬁned as doubling of baseline creatinine
before day 60. Using univariable and multivariable Cox regression
models, hazard ratios for associations of risk factors with CKD
were estimated. Results: A total of 1593 patients, with 279 cases of
CKD (17.5%), made up the study sample. The 279 cases of CKD
occurred at a median of 108 days posttransplantation, with a range
of 100–517 days. In a multivariable Cox regression model, adjusted
for age, sex, diagnosis, donor and transplantation type, total body
irradiation (TBI), cyclosporine prophylaxis, and acute and chronic
GVHD, ARF was a signiﬁcant predictor of CKD (hazard rate 
2.0, 95% comfodence interval  1.6–2.6). Age, mean total serum
bilirubin through day 100, grades 3 and 4 acute GVHD, and
chronic GVHD were also signiﬁcantly associated with CKD after
adjusting for all other factors. TBI and donor and transplantation
type were not associated with an increased risk of CKD in the
multivariable model. Conclusions: The prevalence of CKD to 1
year posttransplantation is 17.5%. ARF, jaundice, severe acute
GVHD, and chronic GVHD are associated with an increased risk
of CKD. Those patients with ARF who survive beyond day 100
should be considered for intervention trials as they are at highest
risk.
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